Cargando…
Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL
Belzutifan was recently approved for the management of Von Hippel–Lindau disease (VHL). Given the morbidity of recurrent treatment, systemic therapy to reduce or eliminate the need for surgery has been long-awaited. Herein, we sought to gain insight about future utilization by surveying VHL kidney c...
Autores principales: | Arevalo, Aileen, Patel, Neal, Muraki, Peter, Ohtake, Shinji, Bratslavsky, Gennady, Clark, Chandra, Mann, Joshua, Iliopoulos, Othon, Jonasch, Eric, Srinivasan, Ramaprasad, Shuch, Brian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Codon Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551368/ https://www.ncbi.nlm.nih.gov/pubmed/36310638 http://dx.doi.org/10.15586/jkcvhl.v9i3.245 |
Ejemplares similares
-
Von Hippel-Lindau is Associated to Pancreatic Neuroendocrine Tumors: A Comprehensive Review
por: Coco, Danilo, et al.
Publicado: (2023) -
SYST-18 BELZUTIFAN TREATMENT FOR PATIENTS WITH VON HIPPEL-LINDAU DISEASE–ASSOCIATED CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS ENROLLED IN THE PHASE 2 LITESPARK-004 STUDY
por: Narayan, Vivek, et al.
Publicado: (2023) -
HIF2a inhibitors for the treatment of VHL disease
por: Metelo, Ana Martins, et al.
Publicado: (2015) -
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling
por: Marathe, Dhananjay D., et al.
Publicado: (2023) -
First clinical experience with belzutifan in von Hippel–Lindau disease associated CNS hemangioblastoma
por: Dhawan, Andrew, et al.
Publicado: (2022)